Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528318 · ClinicalTrials.gov registry record · Phase 2
Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
A Phase 2 study, sponsored by Windtree Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02528318 is a Phase 2 study that was terminated before completion, run by Windtree Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT02528318, a Phase 2 study, was terminated before completion, sponsored by Windtree Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and tolerability of lucinactant for inhalation, administered as an aerosol in up to four escalating doses to preterm neonates 26 to 28 weeks gestational age who are receiving nCPAP for RDS compared to neonates receiving nCPAP alone.
Interventions
- DEVICE nCPAP alone
- COMBINATION_PRODUCT Lucinactant for inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02528318
The ClinicalTrials.gov registry entry for NCT02528318 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nCPAP alone is the first listed.
NCT02528318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02528318 about?
NCT02528318 is a clinical study titled "Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA". This study is to evaluate the safety and tolerability of lucinactant for inhalation, administered as an aerosol in up to four escalating doses to preterm neonates 26 to 28 weeks gestational age who are receiving nCPAP for RDS compared to neonates receiving nCPAP alone.
What is the current status of trial NCT02528318?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-08. Estimated completion is 2017-08-11.
What interventions are being tested in trial NCT02528318?
The interventions under investigation include: nCPAP alone (DEVICE), Lucinactant for inhalation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02528318?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.